C entral venous catheters (CVCs) are usually required in patients admitted to the intensive care unit (ICU). In Europe, the incidence density of CVCrelated bloodstream infections (BSIs) ranges from 1 to 3.1 per 1,000 patient days (1). In the United States, 15 million CVC days are estimated to occur each year in ICU patients, as well as about 80,000 CVC-related BSIs (2, 3). The attributable mortality of CVC-related BSIs has been reported to range from 0% to 11.5%, and the excess ICU length of stay (LOS) has been estimated at 9 -12 days (4, 5). The attributable cost of catheterrelated BSIs varies between $3,124 and $60,536 (6 -13). Consequently, decreasing the incidence of CVC-related BSIs is an important objective.
C entral venous catheters (CVCs) are usually required in patients admitted to the intensive care unit (ICU). In Europe, the incidence density of CVCrelated bloodstream infections (BSIs) ranges from 1 to 3.1 per 1,000 patient days (1) . In the United States, 15 million CVC days are estimated to occur each year in ICU patients, as well as about 80,000 CVC-related BSIs (2, 3) . The attributable mortality of CVC-related BSIs has been reported to range from 0% to 11.5%, and the excess ICU length of stay (LOS) has been estimated at 9 -12 days (4, 5) . The attributable cost of catheterrelated BSIs varies between $3,124 and $60,536 (6 -13) . Consequently, decreasing the incidence of CVC-related BSIs is an important objective.
Several publications suggest that the concomitant implementation of multiple preventive strategies, or bundles, may be required. These interventions include staff education, maximal barrier precautions for catheter insertion, use of chlorhexidine for skin antisepsis, preferential use of the subclavian site for CVC insertion, prompt removal of unnecessary catheters, surveillance, and feedback (14, 15) . Infection-prevention bundles may diminish CVC-related BSI rates to Ͻ2/ 1,000 CVC days (16 -18) . The Dressing Study (19) demonstrated that chlorhexidine gluconate-impregnated sponges (CHGIS) (Biopatch, Ethicon, Somerville, NJ) further decreased the low baseline CVC-related BSI rate, from 1.4 to 0.6/ 1,000 catheter days. In the same study, catheter colonization rates were not significantly increased by changing unsoiled Background: The randomized two-way factorial Dressing Study (1,636 patients, 28,931 catheter days) showed that a chlorhexidine-impregnated sponge decreased the incidence of major catheter-related infections from 1.4‰ to 0.6‰ catheter days, and that scheduled dressing changes every 7 days was not inferior to scheduled changes every 3 days. Here, we assessed the cost benefits of chlorhexidine-impregnated sponge use.
Methods: Costs directly related to major catheter-related infections and the costs of chlorhexidine-impregnated sponge and contact dermatitis were calculated prospectively using microcosting methods during the original study. The added length of stay in the intensive care unit due to major catheter-related infection was estimated using the disability model and assuming a cost of $2,118/intensive care unit day. The cost of each strategy was estimated based on all costs and on the probability of major catheter-related infection according to the Dressing Study results.
Interventions: None. Results: Median direct cost of major catheter-related infection was $792. Estimated added length of stay due to major catheterrelated infection was 11 days (95% confidence interval [؊2 days; adherent catheter dressings every 7 days instead of every 3 days.
In 2007 in France, the cost of one CHGIS was 7.1€ ($9.73 U.S.). Whether CHGIS use for CVC dressings is cost effective needs to be evaluated in ICUs where infection-prevention bundles are implemented routinely, particularly since other devices, such as antiseptic-impregnated catheters, are also available (20) . Our objective here was to assess the economic impact of CHGIS use for arterial of central vein catheters from an ICU perspective.
METHODS

Study Population
We used data from the Dressing Study (19) done in seven ICUs (two medical, two surgical, and three medical-surgical) in three university and two general hospitals in France. Members of the Dressing Study Group are listed in the appendix. This randomized, controlled, clinical trial compared CHGIS and standard dressings and compared changing unsoiled adherent dressings every 7 days and every 3 days. The main outcome was the rate of major catheter-related infections (MCRIs) defined using French (21) and U.S. guidelines as catheterrelated BSIs and systemic catheter-related sepsis without bacteremia (19 (19) .
An economic evaluation was planned in the original study. We used microcosting techniques to prospectively measure direct costs of MCRIs and costs of dressings during the study. We also estimated the additional ICU LOS related to MCRI, using data from the study cohort, which included Ͼ80% of all patients having at least one arterial catheter or CVC in the seven ICUs.
The study was approved by the institutional review board of the Grenoble University Hospital, France.
Study Design
We used a decision tree to represent the therapeutic choices corresponding to the four randomization groups (two decision nodes) and MCRI occurrence (one random event node), in this order: CHGIS or no CHGIS, 7-day dressing change or 3-day dressing change, and MCRI ( Fig. 1 ). The reference strategy was a standard dressing changed every 3 days. The probability of MCRI in the reference group was the MCRI rate found in the Dressing Study in this group, and 95% CIs were obtained by bootstrap resampling. The MCRI probabilities in the other three groups were calculated by multiplying the HRs obtained in the Dressing Study using the control group as the reference (see Supplemental Digital Content 1, http://links.lww.com/CCM/ A323). The expected cost per catheter associated with the end of each strategy branch was obtained by multiplying the overall cost of the strategy by the MCRI probability. The difference between the costs with and without MCRI was the estimated cost of each strategy. The mean 2007 exchange rate was used to convert costs from Euros to U.S. dollars (1 U.S. dollar ϭ 0.73 €).
Inputs
The following were taken into account to estimate the cost of each strategy: number of planned and unplanned dressings (dressing replaced before scheduled time for being soiled or not adherent), treatment of CHGIS-induced contact dermatitis, diagnosis of catheter colonization, direct cost of treating MCRI, and MCRI-related additional ICU LOS. We did not take into account possible costs related to dying from MCRI (4, 5, 11) since the analysis was conducted from the perspective of the ICU. All costs were calculated based on 2007 values.
Cost of Dressings. The cost per dressing was estimated using a microcosting analysis of data from an audit of randomly chosen dressing procedures. In each center, we measured the time needed per dressing, the number of nurses involved, and the material used. Then, the mean cost thus obtained was weighted by the number of dressings performed in each center. The cost of a standard dressing was $9.08 (see Supplemental Digital Content 1, http://links.lww.com/CCM/A323). The CHGISs were purchased from Ethicon at the 2007 commercial price of $9.73, which was added to the cost of a standard dressing to estimate the cost of a CHGIS dressing. The median number of dressings in each randomization group was used for calculations in the decision tree.
Cost of Treating Contact Dermatitis Caused by CHGIS. The condition of the skin was described using the International Contact Dermatitis Research Group system (0, normal; 1, mild redness; 2, redness and slight thickening; 3, intense redness and swelling with coalesced large blisters or spreading reaction) (22) . Only stages 2 and 3 were considered to indicate contact dermatitis in our analysis. The rate of dermatitis for the 3 and 7 days strategies were, respectively, 1.1 and 4.1/1,000 catheters. In the Dressing Study, contact dermatitis required four standard dressings (4 ϫ $9.08), removal of the catheter, and insertion of a new catheter. A microcosting approach was used to estimate the cost of catheter removal ($38.20) and insertion (mean of arterial and central venous catheters, $153.40). Workforce cost is already included in each component.
Cost of Diagnosing Catheter Colonization.
We assumed that the cost of diagnosing catheter colonization included the costs of a catheter culture ($29.60) and antibiotic susceptibility testing when the culture result was positive ($14.80). These costs were obtained from the Grenoble University Hospital's accounts department. The colonization rate was calculated for each randomization group and multiplied by the cost of diagnosing catheter colonization to obtain an estimated cost for each decision-tree branch.
Treatment of Catheter-Related Infections. A microcosting analysis was performed on the 29 MCRI cases to accurately measure the cost of MCRI treatment at the catheter level. The case of each patient was reviewed by a nurse and an intensivist to determine which extra treatments and cares were directly induced by MCRI and therefore deserved inclusion in the cost estimate. Great attention was given to avoid double counting between MCRI treatments costs and routine ICU cares costs. Detailed direct and indirect costs (e.g., staff time) were provided by the accounts department of the participating centers. Median cost was $792.30 (range, $202-$4,445) (see Supplemental Digital Content 1, http://links.lww.com/CCM/A323).
Additional LOS. The additional LOS in the ICU related to MCRIs was estimated using the multi-state disability model (23) . Briefly, this approach averages the difference in LOS at each day (t) between infected and noninfected patients. Its main advantage over other LOS estimating techniques is to take into account censoring events, such as death and discharge. The estimated additional LOS due to MCRI was 11 days (95% CI [Ϫ2 days; 26 days]; p ϭ .12) (see Supplemental Digital Content 1, http://links.lww.com/CCM/A323).
This duration was multiplied by the cost of 1 ICU day calculated using data from the Grenoble University Hospital accounting department for medical and surgical ICUs (this hospital participates in the French national cost database). The cost of 1 ICU day was estimated at $2,118, not counting laboratory tests, imaging studies, or surgical procedures. The overall cost of one MCRI was estimated as the sum of direct costs of MCRI treatment and of the cost of the additional LOS.
Main Assumptions Used for the Cost Analysis. Although most costs were estimated from direct observations, we made several assumptions: 1) the cost of MCRI was independent from the outcome (survival or death); 2) catheter colonization without MCRI had no costs (after the diagnosis) or adverse outcomes; and 3) the estimated cost per ICU day at the Grenoble University Hospital (two of the seven ICUs involved in the Dressing Study) was comparable to the cost in the other five Dressing Study ICUs.
Sensitivity Analyses
Several sensitivity analyses were performed to assess how cost components affected the estimated cost of MCRI and to identify costsaving thresholds. In one-way sensitivity analyses, the following parameters were made to vary: overall cost of one MCRI, MCRI rate, and preventive effect of the CHGIS dressing. A two-way sensitivity analysis was performed by simultaneously varying the MCRI rate and the overall cost of one MCRI.
Statistical Analysis
Patients with and without MCRI were compared using the Fisher's exact test for qualitative variables and the Wilcoxon test for quantitative variables. Nonparametric 95% CIs for the additional LOS were computed using bootstrap resampling. The same approach was used to compute 95% CIs for the MCRI probability in the control group. The disability model in the "ChangeLos" package on the R 2.8.1 software was used to estimate the additional LOS (24) . Analyses were performed using SAS (version 9.1, SAS Institute, Cary, NC) and R (R foundation for statistical computing, Vienna, Austria) software; p values of Ͻ5% were considered significant.
RESULTS
The only variables that differed significantly between patients with and without MCRI were LOS (median, 30 days vs. 10 days, p Ͻ .0001) and number of dressing changes (median, 5 vs. 3, p Ͻ .0001), as shown in Table 1 . Thus, disease severity at ICU admission was not significantly different between patients with and without MCRI. The inputs used in the decision-tree analysis are shown in Table 2 . We estimated the overall cost of one MCRI at $24,090. Expected savings per catheter compared to the reference branch were $197 with the 3-day CHGIS strategy, $133 with the 7-day CHGIS strategy, and $50 with the 7-day standard dressing strategy (Fig. 1) . The cost saving was more pronounced for centers with the highest rate of MCRI.
Excluding workforce cost did not influenced expected savings (see Supplemental Digital Content 7, http://links.lww. com/CCM/A323). When considering only catheter-related BSI, expected savings per catheter compared to the reference branch were $117 with the 3-day CHGIS strategy, $98 with the 7-day CHGIS strategy, and Ϫ$5 with the 7-day standard dressing strategy (see Supplemental Digital Content 6, http://links.lww.com/CCM/A323).
Sensitivity Analyses
The results of the one-way sensitivity analyses are shown in Figure 2 . The greatest variation in estimated cost occurred when the MCRI rate was changed. With the 3-day strategy, CHGIS was cost saving when the baseline MCRI rate was higher than 0.141%, even when the CH-GIS-induced decrease in MCRI risk was no more than 10% or the overall cost per MCRI was greater than $2940. With the 7-day strategy, CHGIS was cost saving when the baseline MCRI rate was higher than 0.212%, even when the CHGISinduced decrease in MCRI risk was no more than 21% (HR ϭ 0.79) or the overall cost per MCRI was greater than $4400. The results of the two-way sensitivity analysis with variations in MCRI rate and MCRI overall cost are shown in Figure 3 . The level-zero curve represents the costsaving threshold.
The analysis was also performed merging the 3-day and 7-day scheduled dressing changes. The cost saved was $164 per catheter (Supplemental Table 8 , Supplemental Digital Content 1, http://links. lww.com/CCM/A323).
DISCUSSION
Using data from the randomized controlled Dressing Study (19), we found that using CHGIS for catheter dressings saved money, decreasing the cost per catheter by at least $83 (7 days rhythm branch: $260-$177). CHGIS remained cost saving when the baseline MCRI rate was as low as 0.212% (0.35 per 1,000 catheter days). Results appear reliable since this study involved seven ICUs and a large number of patients, the data were collected prospectively, and there were no missing data. The direct cost of MCRI and the cost of dressings were calculated prospectively using a microcosting technique.
Infections related to short-term CVCs usually develop via the extraluminal route, indicating a need for improved skin antisepsis (25, 26) . One method for improving skin antisepsis is the use of a CHGIS at the time of CVC insertion. This sponge releases the antiseptic onto the skin for 10 days. A 2006 meta-analysis showed that CHGIS induced a significant decrease in the catheter colonization rate and a nonsignificant decrease in the catheter-related BSI rate (27) . Subsequently, the Dressing Study found a significant decrease in the MCRI rate when CHGIS dressings were used in ICU patients, and a study of hematology patients showed similar benefits (28) .
We found that CHGIS remained cost saving even when the CHGIS-induced decrease in MCRI risk was only 10% with 3-day scheduled changes and 21% with 7-day scheduled changes, which corresponded to the lower limit of the 95% CI for CHGIS efficacy in the Dressing Study.
Since half of the dressings were performed before the planned date (19) because of soiling or leakage, the mean number of dressing saved by the 7-day change strategy was only 0.7 per catheter. It explained the minimal cost saved by the 7-day strategies as compared to the 3-day ones. If we only considered CHGIS impact, the mean cost saved per catheter is $164 (Supplemental Table 8 , Supplemental Digital Content 1, http://links.lww.com/CCM/A323).
Our estimate that the overall cost of each MCRI was $24,090 is consistent with previous estimates, which range from $3,000 to $60,000 (6 -11, 29) . We used an original method for estimating the additional LOS related to MCRI. This method avoids the overestimation of the additional LOS that occurs in matched cohort studies, because the occurrence of MCRI is handled as a time-dependent event instead of as a fixed-time event (30) . Although neither case mix nor disease severity at ICU admission was taken into account, these two variables were not significantly different between patients with and without MCRI in the Dressing Study. The mean cost per ICU day of $2118 used in our study is probably an underestimation, since we did not count the costs of imaging studies or surgical procedures performed outside the ICU during the ICU stay. Furthermore, cost per day was that in a single, large, teaching hospital, which may limit the relevance of our results to other institutions, since patient populations and processes of care may vary. A recent estimate from the United States showed higher costs per ICU day of $3968 for mechanically ventilated patients, and $3184 for patients other patients (31) . Also, we included workforce cost savings in our calculation, although it might be considered as being a constant cost independent from the infection occurrence. However, excluding workforce cost from the analysis did not change the results. Finally, our analysis was done from the perspective of the ICU as opposed to the hospital, third-party payers, individual patient, or society. However, ICUs are most directly affected by the excess costs of nosocomial infection in the prospective payer system, and are responsible for purchasing new technologies designed to prevent these infections. CHGIS was still cost saving assuming a cost per ICU day of $2,940 with dressing changes every 3 days, and $4,400 with dressing changes every 7 days.
In the 2010 Centers for Disease Control recommendations, the use of CHGIS is recommended (grade 1B recommenda- tion) if the catheter-related infection rate is high despite adequate infectionprevention bundles (32) . We demonstrated that CHGIS was cost saving even when the baseline MCRI rate was as low as 0.14% (0.23 per 1,000 catheter days) with 3-day changes, and 0.21% (0.35 per 1,000 catheter-days) with 7-day changes. These low levels were seen in only about one quarter of ICUs in the postintervention program in Michigan (18) , fewer than one quarter of ICUs in the French REA-RAISIN network, and fewer than half the ICUs involved in the 2006 -2008 catheter-related BSI Centers for Disease Control program (33) . Last, in the postimplementation phase of the keystone ICU project, the mean infection rate was 1.1 per 1,000 catheter days (34) .
The 2% chlorhexidine antiseptic preparation was not available for skin antisepsis during the study. It is possible that some of the observed benefits of the CHGIS dressing would have been attenuated if 2% chlorhexidine had been used, although no trial has demonstrated that chlorhexidine is superior to the alcoholbased povidone-iodine formulation used in the study (26) .
Whether our results apply to all arterial and venous catheters in ICU patients deserves discussion. In previous studies, there was no difference in the risk of infection between arterial catheters and CVCs (35) (36) (37) , and in the Dressing Study, the effect of CHGIS on the MCRI rate was similar for arterial catheters (HR ϭ 0.39) and CVCs (HR ϭ 0.42). Similarly, the baseline MCRI incidence was higher than the cost-saving threshold of 0.35/1,000 catheter days for all insertion sites of arterial catheters and CVCs (arterial: radial, 1.90/1000 catheter days and femoral, 1.9/1000 catheter days; central vein: internal jugular, 2.46/1,000 catheter days; femoral, 1.09/1,000 catheter days; and subclavian, 1.06/1,000 catheter days). Thus, there was no specific catheter site at which CHGIS was not beneficial.
We noted that use of CHGIS required specific training of healthcare workers. This training was delivered during the Dressing Study (19) . In the cost-analysis study, neither the cost of training nor the learning curve was taken into account.
The cost benefits of CHGIS found in our study were comparable to those obtained using catheters treated with antiinfective agents (38) . As an example, Veenstra et al (39) determined that regular use of chlorhexidine-silver sulfadiazine-coated catheters rather than a standard uncoated catheter would save $59,000 per 300 catheters if the infection rate was 5.2% using standard uncoated catheters. However, the cost benefits of such catheters have not been assessed in ICUs where infection-prevention bundles are implemented routinely (20) .
We conclude that the use of CHGIS is cost saving in ICUs, even when the baseline MCRI rate is low.
